Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Minhas, Muhammad U." wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł:
DETERMINATION OF ACYCLOVIR IN RABBIT PLASMA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC (HPLC) TECHNIQUE
Autorzy:
Malik, Nadia S.
Ahmad, Mahmood
Minhas, Muhammad U.
Khalid, Qandeel
Powiązania:
https://bibliotekanauki.pl/articles/895236.pdf
Data publikacji:
2019-06-28
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
plasma
acyclovir
Reversed phase high-performance liquid chromatography
Opis:
A rapid, sensitive and simple reversed-phase high-performance liquid chromatographic (HPLC) method has been developed and validated for the determination of acyclovir (ACV) in rabbit plasma. BDS C18 column was used to conduct analysis using ammonium dihydrogen phosphate buffer (50mM) and methanol as mobile phase (98:2), with pH adjusted to 2.5 using orthophosphoric acid. Flow rate was kept at 1 mL/min. Selective precipitation of plasma proteins were done by adding 5% perchloric acid. Precipitated plasma proteins were separated by centrifugation. ACV moves in a supernatant, which was snapped and passed through a syringe filtration assembly. Direct injection of supernatant was given into a BDS C18 column and ACV was detected at 256 nm. The limit of detection for ACV in plasma was estimated as 15ng/mL whereas the limit of quantitation was calculated as 25 ng/mL. Moreover, the developed method has been found to be selective and linear into concentration range of 25 – 2000 ng/mL. The present method could be successfully applied to samples from bioavailability and bioequivalence studies.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 3; 421-429
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
USE OF GLUTARIC ACID TO IMPROVE THE SOLUBILITY AND DISSOLUTION PROFILE OF GLIPIZIDE THROUGH PHARMACEUTICAL COCRYSTALLIZATION
Autorzy:
Batool, Fakhra
Ahmad, Mahmood
Minhas, Muhammad U.
Khalid, Qandeel
Idrees, Hafiz A.
Khan, Fahad M.
Powiązania:
https://bibliotekanauki.pl/articles/895470.pdf
Data publikacji:
2019-02-28
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
FTIR
SEM
PXRD
thermal analysis
glipizide
glutaric acid
Opis:
The purpose of current study was to improve the solubility and dissolution profile of BCS class-II drug Glipizide using glutaric acid as a coformer via various cocrystalization techniques i.e., dry grinding, liquid assisted grinding, slurry and solvent evaporation. Fourier Transform Infrared Spectroscopy (FTIR) was performed to determine the interaction between components of glipizide-glutaric acid (GPZ-GLU) cocrystals. Powder X-ray Diffraction (PXRD) studies confirmed the crystalline nature of formulated cocrystals. Scanning Electron Microscopy (SEM) revealed cylindrical to rectangular shape of cocrystals. Flow properties of GPZ-GLU cocrystals were evaluated by micromeritics analysis. Size and surface morphology was determined by zeta sizer analysis and optical microscopy. Differential scanning calorimetry (DSC) and Thermogravimetric (TGA) analysis were performed to determine the melting points as well as thermal stability of pure components and formulated GPZ-GLU cocrystals. In-vitro drug release studies were carried out using dissolution apparatus-II. GPZ-GLU cocrystals showed higher drug release at pH 6.8 as compared to pH 1.2. However, percent drug release of optimum formulations at pH 6.8 was determined as; 24%-92.2% (F3) and 12.0%-93.5% (F7). Solubility studies revealed improved solubility as compared to pure drug in water i.e., 53 folds and 54.27 folds from F3 and F7 cocrystals, respectively. Finally it was concluded that glutaric acid has improved the solubility and dissolution profile of glipizide. However, many cocrystal formers have been reported in literature that can be used to enhance the physicochemical properties as well as bioavailability of poorly soluble drugs via cocrystalization technique.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 1; 103-114
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Toxicological evaluation of xanthan gum based hydrogel formulation in Wistar rats using single dose study
Autorzy:
Malik, Nadia S.
Ahmad, Mahmood
Minhas, Muhammad U.
Tulain, Ruqia
Khalid, Ikrima
Barkat, Kashif
Rashid, Ayesha
Powiązania:
https://bibliotekanauki.pl/articles/895609.pdf
Data publikacji:
2020-04-29
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
rats
Histopathology
Hydrogel
acute toxicity
Maximal tolerated dose
Opis:
Xanthan gum-based hydrogel formulation FXG3 was prepared by a free radical polymerization technique. To assess safety of FXG3 hydrogel for potential application as new drug delivery system, a single oral dose toxicity study was conducted according to OECD guidelines. Female adult rats of Wistar strain were divided into group A and group B. Group A served as the control and was given 1mL/100 g body weight 0.9% saline. Group B received a dose of 5g/kg body weight of FXG3 hydrogel. Rats were observed continuously for 14 days for clinical signs, and prior to terminal sacrifice, blood samples were taken to assess for haematology and biochemical parameters. Selected organs (heart, liver, lung, kidneys, spleen, and stomach) were removed and examined macroscopically, washed, sliced and stained with haematoxylin-eosin for histopathological investigation. No mortality or any signs of acute toxicity was observed during the observation period. No macroscopic alteration was found in the selected organs. Histopathological examination did not show any pathological changes. Thus, the maximal tolerated dose of FXG3 was calculated to be higher than 5g/kg body weight. It can be concluded that FXG3, a xanthan gum-based hydrogel formulation, was non-toxic after acute oral administration at 5g/kg body weight, and thus may be a promising candidate in controlled drug delivery system.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 2; 353-360
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies